ADPT:NYE-Adaptive Biotechnologies Corporation (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 39.45

Change

0.00 (0.00)%

Market Cap

USD 5.54B

Volume

0.77M

Average Target Price

USD 62.40 (+58.17%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

N/A

USD191.19B 27.45 3.25
BHVN Biohaven Pharmaceutical Holdin..

N/A

USD6.18B N/A N/A
MYOV Myovant Sciences Ltd

N/A

USD1.93B N/A N/A
ADCT ADC Therapeutics SA

N/A

USD1.82B -99,999.99 N/A
ZYME Zymeworks Inc

N/A

USD1.67B 300.20 N/A
RCUS Arcus Biosciences, Inc

N/A

USD1.65B N/A N/A
CVM CEL-SCI Corporation

N/A

USD0.94B N/A N/A
RFL Rafael Holdings, Inc

N/A

USD0.79B N/A N/A
ANVS Annovis Bio, Inc

N/A

USD0.65B -99,999.99 N/A
LCTX Lineage Cell Therapeutics, Inc

N/A

USD0.44B 3.63 N/A

ETFs Containing ADPT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -33.28% 14% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -33.28% 14% F 2% F
Trailing 12 Months  
Capital Gain -11.80% 26% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.80% 26% F 6% F
Trailing 5 Years  
Capital Gain -20.72% 25% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.72% 25% F 12% F
Average Annual (5 Year Horizon)  
Capital Gain 562.80% 99% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 562.80% 99% A+ 99% A+
Risk Return Profile  
Volatility (Standard Deviation) 1,017.68% 2% F 2% F
Risk Adjusted Return 55.30% 81% B- 73% C
Market Capitalization 5.54B 93% A 74% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 43.96 20% F 18% F
Price/Book Ratio 7.70 32% F 13% F
Price / Cash Flow Ratio -36.98 93% A 94% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -24.34% 84% B 14% F
Return on Invested Capital -23.25% 75% C 6% F
Return on Assets -10.24% 89% B+ 4% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.05 61% D- 26% F
Short Percent 4.77% 50% F 41% F
Beta 0.49 76% C 82% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector